Eleven-Year Experience with the Avidin-Biotin Pretargeting System in Glioblastoma: Toxicity, Efficacy and Survival


Background: The 3-step avidin-biotin pretargeting approach is applied in patients with recurrent glioblastoma (GBM), using biotinylated anti-tenascin monoclonal antibody as the first step of pretargeting followed by avidin and 90 Y- 


1 Figure or Table

Slides referencing similar topics